Navigating Zepbound Availability: What Doses Are Experiencing Shortages?

Last reviewed: June 28, 2026

Last updated: June 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide injection) has faced repeated supply disruptions since its 2023 FDA approval, with shortages affecting multiple dose strengths at different times. Patients navigating these delays often struggle to find reliable access to this dual GLP-1/GIP receptor agonist. PlexusDx provides a stable alternative through compounded tirzepatide formulated by licensed 503A pharmacies, offering consistent availability across all dose levels.

Which Zepbound Doses Face the Longest Shortages?

Zepbound shortages have rotated across dose strengths throughout 2023 and 2024, with mid-range and higher-dose formulations experiencing the most severe supply gaps. The 5 mg and 10 mg doses frequently report longer lead times at major pharmacy chains, while lower starter doses occasionally stabilize first due to lower overall demand. Manufacturing constraints at Eli Lilly facilities, combined with surging demand for GLP-1 therapy, have created unpredictable allocation patterns that force prescribers and patients to adjust treatment plans mid-therapy.

Patients already established on a specific Zepbound dose sometimes face abrupt switches to alternative strengths or lengthy delays that disrupt their weight loss progress. These interruptions can reset metabolic adaptation and increase the risk of weight regain during the pause. The lack of transparent shortage forecasting makes it difficult for patients to plan ahead or secure their next month's supply with confidence.

Why Compounded Tirzepatide Offers Reliable Access

Compounded tirzepatide manufactured by licensed 503A pharmacies operates through a different supply network than brand-name Zepbound, reducing exposure to the same shortage factors. These pharmacies source active pharmaceutical ingredients (APIs) from FDA-inspected suppliers and formulate individual doses on demand, rather than relying on pre-manufactured bulk inventory. This approach allows PlexusDx to maintain consistent availability without membership fees, insurance barriers, or long wait times that plague retail pharmacy chains.

PlexusDx tirzepatide injection starts at $249 monthly and works identically to Zepbound at the cellular level—both activate the same GLP-1 and GIP receptors to reduce appetite and improve metabolic function. The compounding model means patients can adjust their dose without purchasing an entirely new pen, and their monthly cost remains flat regardless of strength. All formulations are prepared in licensed 503A facilities under strict quality and sterility standards verified by state pharmacy boards.

Understanding the Difference Between Compounded and Brand-Name Supply

Brand-name Zepbound relies on Eli Lilly's centralized manufacturing, storage, and distribution network. When production capacity falls short of demand—as it has repeatedly—the entire supply chain experiences bottlenecks that trickle down to pharmacy shelves. Shortages are published by the FDA and wholesalers, but individual patients often discover them only when trying to fill a prescription, leaving no time to find an alternative.

Compounded tirzepatide follows federal pharmacy regulations (USP standards and state board oversight) but is prepared by independent 503A compounders who purchase ingredients separately and formulate to order. This decentralized model reduces single-point failure risk and allows PlexusDx to source from multiple licensed suppliers. Because compounded medications are made after a patient's prescription is filled—not manufactured months in advance—supply constraints are far less likely to disrupt treatment continuity.

How PlexusDx Personalization Optimizes Your Tirzepatide Therapy

Beyond supply stability, PlexusDx adds a precision medicine layer through the Precision Peptide Genetic Test, which maps 14 metabolic pathways and 49 peptides linked to weight regulation. Key genetic variants—including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—influence how your body responds to tirzepatide and other GLP-1/GIP compounds. Understanding your genetic predispositions helps clinicians set realistic dose expectations and identify which formulation (injection vs. oral) aligns with your metabolism.

The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment and provides 150+ genetic insights specific to your peptide pathways. This testing is not pharmacogenomic (drug metabolism); instead, it profiles your underlying biology to predict response likelihood and personalize your treatment plan. Patients with certain genetic profiles may thrive on compounded tirzepatide, while others might benefit from a dual-compound option like GLP-Squared Injection—all without flat per-compound pricing changes, because PlexusDx pricing remains flat across commitment tiers.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded tirzepatide as effective as Zepbound?

Yes. Compounded tirzepatide contains the same active molecule (tirzepatide) and activates identical GLP-1 and GIP receptors as brand-name Zepbound. Clinical efficacy depends on dose strength and patient adherence, not manufacturing source. PlexusDx compounded tirzepatide is prepared by licensed 503A pharmacies under FDA inspection and USP standards, ensuring purity and potency equivalent to brand formulations.

What clinical trials support tirzepatide for weight loss?

Tirzepatide demonstrated superior weight loss compared to semaglutide in the SURMOUNT clinical trial series, with patients achieving 20-25% body weight reduction at higher doses over 68 weeks. The dual GLP-1/GIP mechanism produces greater appetite suppression and metabolic improvement than GLP-1 alone, making it a first-line option for patients with obesity or type 2 diabetes. Both brand and compounded formulations deliver equivalent pharmacological effects.

How much does PlexusDx tirzepatide cost, and do prices change with dose?

PlexusDx compounded tirzepatide injection starts at $249 per month on a one-month commitment and remains flat across all dose strengths and three commitment tiers. No insurance is required, and the medication is HSA/FSA eligible. Your dose may increase as your body adapts, but your monthly price stays the same—a transparent pricing model that protects you from escalating costs.

Are there any safety concerns specific to compounded tirzepatide?

Compounded tirzepatide carries the same safety profile as brand Zepbound: potential nausea, vomiting, diarrhea, and rare pancreatitis or thyroid concerns. The difference is quality assurance—PlexusDx sources from licensed 503A pharmacies subject to state board inspection and FDA oversight. Always disclose compounded medication use to your healthcare provider and monitor for adverse effects consistently.

How can the Precision Peptide Genetic Test improve my tirzepatide outcome?

The Precision Peptide Genetic Test ($99 add-on) analyzes 150+ genetic insights across 14 metabolic pathways to predict your response to tirzepatide and similar peptides. Key variants like GLP1R rs6923761 and GIPR rs1800437 influence receptor sensitivity; FTO rs9939609 and MC4R rs17782313 affect baseline appetite regulation. This data helps your clinician optimize your dose strategy and choose between injection, oral, or dual-compound formulations to match your genetic profile.

Related Reading

• Zepbound Doses
• Fridays Zepbound
• Hims Zepbound
• Form Health Zepbound

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.